9EN Stock Chart & Stats
€31.70
€0.30(1.02%)
At close: 4:00 PM EDT
€31.70
€0.30(1.02%)
Day’s Range― - ―
52-Week Range€17.80 - €38.25
Previous CloseN/A
Volume0.00
Average Volume (3M)25.00
Market Cap
€2.32B
Enterprise Value€1.99K
Total Cash (Recent Filing)€318.28M
Total Debt (Recent Filing)€673.73K
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Nov 18, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding69,863,686
10 Day Avg. Volume37
30 Day Avg. Volume25
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€53.52Price Target Upside68.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 EfficacyThe strong Phase 3 prophylaxis result materially improves the credibility of deucrictibant XR and supports Pharvaris’s potential competitive position. Consistent efficacy across subgroups and significant secondary endpoints strengthen the case for a durable oral HAE franchise.
Regulatory Progress And Funding RunwayAdvancing U.S. and European regulatory reviews move the lead program closer to commercialization, while substantial cash resources support continued trials and pre-commercial preparation. The reported runway into 2028 reduces near-term financing pressure during key approval milestones.
Very Low LeverageMinimal debt gives Pharvaris financial flexibility as it funds late-stage development and prepares for potential launches. Low leverage limits interest and refinancing exposure, allowing available capital to remain focused on clinical programs, regulatory work, and commercialization.
Bears Say
No Product RevenueThe company has not yet demonstrated recurring commercial revenue, so its future economics remain dependent on clinical success, regulatory approval, and eventual launch execution. Until a product reaches the market, operating performance cannot be supported by an established sales base.
Persistent Cash BurnSustained negative operating and free cash flow shows that Pharvaris must continue funding development and operations without internal cash generation. Even with reported liquidity, prolonged burn can require future external financing and may constrain capital allocation if commercialization is delayed.
Widening LossesDeep and persistent losses indicate that the operating cost base is expanding ahead of revenue and that profitability is not yet on an improving trajectory. Negative returns on equity also show that shareholder capital is currently being consumed rather than converted into earnings.
Pharvaris News
9EN FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was €17.80 and its highest was €38.25 in the past 12 months.
What is Pharvaris’s market cap?
Pharvaris’s market cap is €2.32B.
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Nov 18, 2026 which is in 62 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Aug 12, 2026. The company reported -€0.7 earnings per share for the quarter, missing the consensus estimate of -€0.654 by -€0.046.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate is -0.72.
How many shares outstanding does Pharvaris have?
Pharvaris has 69,863,686 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -€0.7 in its last earnings report, missing expectations of -€0.654. Following the earnings report the stock price went up 4.69%.
Which hedge fund is a major shareholder of Pharvaris?
Currently, no hedge funds are holding shares in DE:9EN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharvaris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€53.52 (68.83% Upside)
€53.52 (68.83% Upside)
Blogger Sentiment
Bullish
DE:9EN Sentiment 100%
Sector Average 62%
Sector Average 62%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
52.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pharvaris
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
9EN Stock 12 Month Forecast
Average Price Target
€53.52
▲(68.83% Upside)